Today, Saturday, Prime Minister Mr. Mohammed Shia' al-Sudani inaugurated the Mansour and Al-Mustaqbal factories, which specialize in pharmaceutical industries, as part of the government's program to localize drug manufacturing and increase self-sufficiency rates.
His Excellency affirmed the continuation of the goal to develop and increase the production of local medicines; to achieve pharmaceutical security by working on localizing the pharmaceutical industry and encouraging national products; and that contracts for local medicines have increased threefold, which represents a positive indicator.
The Prime Minister explained that the increase in pharmaceutical production has led the government to encourage, support, and provide all the necessary advantages to ensure the success of these projects, starting with banking support and the sovereign guarantees available for these projects. He confirmed that the registration of pharmaceutical companies is proceeding smoothly, and comprehensive, detailed instructions have been put in place to facilitate the transfer of technology to national factories and to ease partnerships with specialized foreign companies and the private sector.
His Excellency pointed out the importance of establishing the concept of "Made in Iraq" as a national goal that everyone shares, emphasizing the need to cover the needs of all chronic diseases before the middle of next year, in addition to cancer treatments, in cooperation with the private sector.
The Mansour factory, which was reopened following government decisions to localize the pharmaceutical industry, includes two lines for producing therapeutic syrups with a capacity of 14 million bottles annually, two lines for producing tablets with a capacity of 140 million tablets annually, and has been supplemented with a factory for producing cancer treatment drugs, a factory for producing intravenous solutions, in addition to a line for producing eye drops.
As for the future factory, it will produce more than 300 pharmaceutical forms, including the production of intravenous solutions with a capacity of 18 million bottles annually, providing more than 15 types of life-saving drugs, the production of ampoules with a capacity of 110 million ampoules annually, and the production of eye drops with a capacity of 15 million bottles annually. It is designated for the production of more than 60 types of medicines and antibiotics, in addition to manufacturing anti-cancer drugs, for which a contract will be signed to transfer the technology to produce more than 12 types of them.
#Year_of_Achievements
The Media Office of the Prime Minister
November 2, 2024